about
Pazopanib in the management of advanced soft tissue sarcomasThe Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review.A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndromeIdentification of target genes of cediranib in alveolar soft part sarcoma using a gene microarray.Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapiesEmerging therapies for adult soft tissue sarcoma.Vascular endothelial growth factor receptor-2 inhibitor cediranib causes regression of endometriotic lesions in a rat modelTyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.New ways to successfully target tumor vasculature in ovarian cancer.A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.Decreased serum level and increased urinary excretion of vascular endothelial growth factor-C in patients with chronic kidney diseaseCellular factors implicated in filovirus entryAngiogenesis-related pathways in the pathogenesis of ovarian cancerReceptor Tyrosine Kinase and Tyrosine Kinase Inhibitors: New Hope for Success in Multiple Sclerosis TherapyTargeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.The role of Cediranib in ovarian cancer.
P2860
Q26746205-331518D1-0B28-4EF8-8D12-6C147A7B9DC3Q30248645-73D1BEBF-4D14-4085-8119-0AB83343B872Q33418285-C081B82D-B31A-4279-9DFC-ADFAEC184575Q33598883-C9D883BC-FB32-4713-A94F-3291967BE194Q34158454-12B7D9CF-0828-4A95-941C-10EF860DD307Q34659806-554B2E0C-50C5-4422-867F-EF83DD3B2750Q35406146-D04C8BB6-DD75-4E8F-AAB7-B942E7D5DD19Q35553882-D35DCD9C-9FE0-4DA1-83D7-EE533E25F1D7Q35928220-92350D7B-1ACD-40F4-A6C1-63151D2F1AFEQ36031619-F7ED7406-FAD1-44F3-84A7-BB8CCA4C2069Q36465664-14995039-66C6-41AA-A17F-292C68875225Q36567284-8CAE5523-DB6B-4E97-8061-6346EC8C4C7EQ37139109-AA2AF4AA-3524-408E-84F9-08D0F31A3B71Q38261946-849C3619-1AE2-40B8-9C64-493E0BBCA10EQ38498207-59D7BDEA-E95C-4CD4-BF3C-D314DF9886F8Q49966031-33D0A4D2-DB40-459D-874E-59BF14D13ACB
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cediranib: a VEGF receptor tyrosine kinase inhibitor.
@en
type
label
Cediranib: a VEGF receptor tyrosine kinase inhibitor.
@en
prefLabel
Cediranib: a VEGF receptor tyrosine kinase inhibitor.
@en
P2093
P2860
P356
P1433
P1476
Cediranib: a VEGF receptor tyrosine kinase inhibitor.
@en
P2093
Fernanda Caparelli
Marina Sahade
Paulo M Hoff
P2860
P304
P356
10.2217/FON.12.73
P407
P577
2012-07-01T00:00:00Z